H2-receptor Antagonist, Roxatidine, and Its Drug-Drug Interactions
|
Accession number;04A0309575
|
| Title;H2-receptor Antagonist, Roxatidine, and Its Drug-Drug Interactions |
| Author;
TANAKA EINOSUKE
(Univ. of Tsukuba, Inst. of Commun. Med.)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.32;NO.1;PAGE.21-30(2004)
|
| Figure&Table&Reference;FIG.1, TBL.2, REF.68 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Metabolic drug interactions are a major source of clinical problems. Recently, the study of drug interactions has extended to the DNA level. Polymorphisms at the DNA level have been reported in many human drug-metabolizing enzymes and it has been shown that their variety and frequency vary considerably among races. In particular, attention has been paid to the cytochrome P450(CYP)2A6, CYP2C9, CYP2C19 and CYP2D6 forms as far as Japanese are concerned. In this article, the interactions of roxatidine, a H2-receptor antagonist, and several drugs (e.g., antipyrine, warfarin, theophylline, propranolol, diazepam, trimethadione) were investigated. It was found that roxatidine was not involved in any interactions with these drugs in clinical study. We conclude that roxatidine will not cause any drug-drug interaction mediated by CYP2C9, CYP2C19 and CYP2D6 isozymes in clinical situations as far as the concomitantly administered drugs used here are concerned. (author abst.) |
|
|
|
Related Articles;
|
|
